New Study Shows Vaginal Oxygen and Hyaluronic Acid Improve Lower Urinary Tract Symptoms in Breast Cancer Survivors
27 March 2025
Genoa, Italy – A groundbreaking study published in Climacteric has found that a combination of vaginal oxygen therapy and hyaluronic acid significantly improves lower urinary tract symptoms (LUTS) in breast cancer survivors. Conducted by a team of researchers from the University of Genoa and IRCCS Ospedale Policlinico San Martino, the study provides hope for women experiencing genitourinary syndrome following cancer treatment.
The prospective trial involved 85 breast cancer survivors undergoing a five-session treatment of intravaginal oxygen administration combined with a 2% hyaluronic acid solution. Results showed a marked improvement in LUTS, with significant reductions in Urogenital Distress Inventory-6 (UDI-6) scores, particularly in irritative, stress, and obstructive discomfort symptoms.
“These findings are a breakthrough for breast cancer survivors who struggle with urinary symptoms due to oestrogen deprivation,” said lead researcher Dr Giorgia Asinaro. “With systemic oestrogen therapies contraindicated in these patients, this non-hormonal treatment offers a promising alternative.”
The study found that patients treated with aromatase inhibitors experienced the greatest benefit. Additionally, those using gonadotrophin-releasing hormone (GnRH) analogs saw notable improvement in irritative symptoms, while tamoxifen appeared to limit the relief of stress symptoms.
“By enhancing oxygenation and hydration of vaginal and urinary tissues, this therapy helps restore tissue function and alleviate discomfort,” explained senior author Dr Angelo Cagnacci. “This offers an innovative, safe, and non-invasive solution for breast cancer survivors.”
The treatment, administered via a specialised medical device (CaressFlow Srl), involves delivering 95% pure oxygen intravaginally, followed by the infusion of hyaluronic acid. Sessions were conducted at 15-day intervals over a total of five sessions, with improvements sustained even at a 60-day follow-up.
Given its promising results, the research team calls for further large-scale studies to validate these findings and explore long-term benefits. As the first study to focus specifically on LUTS in breast cancer survivors, it highlights an urgent need for effective and accessible non-hormonal treatments.
The full study is available online at Climacteric and can be accessed via https://doi.org/10.1080/13697137.2025.2455182].
If you are interested in offering the groundbreaking Caress Flow treatment to your patients or finding out some more information, please contact ellie@lawmed.co.uk.
About Caress Flow
Caress Flow is a leading innovator in women's health, dedicated to providing natural, effective treatments for a range of vaginal conditions. Combining the power of oxygen therapy with the moisturising properties of hyaluronic acid, Caress Flow offers a painless, safe, and clinically proven solution for women’s intimate health needs.
For media inquiries, please contact:
Megan Peek
01702 870190
